Byron Colley, MD
Clinical Cardiac Electrophysiology · Birmingham, ALNPI 1679665640
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (43.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Abbott accounts for 71.0% of it on its own, with 27 other manufacturers making up the rest.
Across 423 payments — averaging $140.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$42K
- Medtronic$8K
- Boston Scientific$5K
- Biosense Webster, Inc.$541
- Novartis$492
- Amgen$376
- plus $2K from 22 others
Across 194 payments — averaging $6160.61 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$826K
- Medtronic$246K
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$122K
- Boehringer Ingelheim$923
What the payments were for
- Consulting fees$25,73843%
- Speaking & faculty fees$5,87510%
- Travel & lodging$12,96422%
- Food & beverage$14,67125%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 163 | $42,088 |
| Medtronic(2 entities) | 21 | $8,063 |
| Boston Scientific | 49 | $5,416 |
| Biosense Webster, Inc. | 9 | $541 |
| Novartis | 31 | $492 |
| Amgen | 33 | $376 |
| Boehringer Ingelheim | 19 | $325 |
| Impulse Dynamics (USA) Inc. | 4 | $299 |
| E.r. Squibb & Sons, L.L.C. | 17 | $236 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 18 | $227 |
| Johnson & Johnson | 18 | $226 |
| Angiodynamics, Inc. | 2 | $201 |
| Pfizer | 9 | $159 |
| Merck | 9 | $158 |
| Atricure, Inc. | 3 | $74 |
| Edwards Lifesciences | 1 | $72 |
| Irhythm Technologies, Inc. | 2 | $50 |
| Sanofi-aventis U.S. LLC | 3 | $40 |
| AstraZeneca | 3 | $36 |
| Cardiva Medical, Inc. | 1 | $25 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Bayer | 1 | $23 |
| Vifor Pharma, Inc. | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| Actelion Pharmaceuticals US, Inc. | 1 | $12 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Perclose ProStyle$6,600
- Accent Pacemaker$6,375
- TACTICATH ABLATION CATHETER, SENSOR ENABLED$6,117
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$3,675
- Farapulse$3,304
- AVEIR$2,208
- ENSITE$1,731
- DiamondTemp$1,456
- AMPLATZER AMULET$1,379
- AMPLATZER Occluders$1,104
- WATCHMAN Access System$861
- ENSITE PRECISION$491
- Carto 3$487
- AMPLATZER TORQVUE 45 X 45$445
- OPTIMIZER$328
- ABSOLUTE PRO$205
- ARTiC-L$145
- COBALT DR MRI SURESCAN$132
- Arctic Front$128
- ADVISOR$128
How this compares
$59,248 in reported general payments places this provider in the 80th percentile of 42 clinical cardiac electrophysiology providers in Alabama.
See all clinical cardiac electrophysiology providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 154 | $113,920 |
| EntrestoSacubitril/Valsartan | 27 | $28,909 |
| XareltoRivaroxaban | 23 | $19,304 |
| Dofetilide | 53 | $8,780 |
| Metoprolol Succinate | 141 | $2,175 |
| Flecainide Acetate | 42 | $1,524 |
| Amiodarone Hcl | 65 | $667 |
| SotalolSotalol Hcl | 23 | $439 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 19 | $372 |
| Propafenone Hcl | 12 | $309 |
| Verapamil ErVerapamil Hcl | 11 | $195 |
| Olmesartan Medoxomil | 17 | $185 |
| Carvedilol | 27 | $163 |
| Potassium Chloride | 26 | $147 |
| Cephalexin | 12 | $73 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $159 | $113,920154 claims |
| NovartisEntresto | $492 | $28,90927 claims |
| Johnson & JohnsonXarelto | $226 | $19,30423 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 42 clinical cardiac electrophysiology providers in Alabama.
Other clinical cardiac electrophysiology in Birmingham
- Hugh McElderryBirmingham$725K
- Anil RajendraBirmingham$495K
- Gustavo MoralesBirmingham$171K
- William MaddoxBirmingham$159K
- Francis BennBirmingham$95K
- Terence DunnBirmingham$73K
- Macy SmithBirmingham$45K
- Chad ColonBirmingham$42K
- Blake SmithBirmingham$36K
- Ahmad JalladBirmingham$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.